PLoS Biology (Jun 2017)

Human cyclophilin 40 unravels neurotoxic amyloids.

  • Jeremy D Baker,
  • Lindsey B Shelton,
  • Dali Zheng,
  • Filippo Favretto,
  • Bryce A Nordhues,
  • April Darling,
  • Leia E Sullivan,
  • Zheying Sun,
  • Parth K Solanki,
  • Mackenzie D Martin,
  • Amirthaa Suntharalingam,
  • Jonathan J Sabbagh,
  • Stefan Becker,
  • Eckhard Mandelkow,
  • Vladimir N Uversky,
  • Markus Zweckstetter,
  • Chad A Dickey,
  • John Koren,
  • Laura J Blair

DOI
https://doi.org/10.1371/journal.pbio.2001336
Journal volume & issue
Vol. 15, no. 6
p. e2001336

Abstract

Read online

The accumulation of amyloidogenic proteins is a pathological hallmark of neurodegenerative disorders. The aberrant accumulation of the microtubule associating protein tau (MAPT, tau) into toxic oligomers and amyloid deposits is a primary pathology in tauopathies, the most common of which is Alzheimer's disease (AD). Intrinsically disordered proteins, like tau, are enriched with proline residues that regulate both secondary structure and aggregation propensity. The orientation of proline residues is regulated by cis/trans peptidyl-prolyl isomerases (PPIases). Here we show that cyclophilin 40 (CyP40), a PPIase, dissolves tau amyloids in vitro. Additionally, CyP40 ameliorated silver-positive and oligomeric tau species in a mouse model of tau accumulation, preserving neuronal health and cognition. Nuclear magnetic resonance (NMR) revealed that CyP40 interacts with tau at sites rich in proline residues. CyP40 was also able to interact with and disaggregate other aggregating proteins that contain prolines. Moreover, CyP40 lacking PPIase activity prevented its capacity for disaggregation in vitro. Finally, we describe a unique structural property of CyP40 that may permit disaggregation to occur in an energy-independent manner. This study identifies a novel human protein disaggregase and, for the first time, demonstrates its capacity to dissolve intracellular amyloids.